Eliminate dark side from antiplatelet therapy
- PMID: 24764558
- DOI: 10.1182/blood-2014-03-560417
Eliminate dark side from antiplatelet therapy
Comment on
-
A talin mutant that impairs talin-integrin binding in platelets decelerates αIIbβ3 activation without pathological bleeding.Blood. 2014 Apr 24;123(17):2722-31. doi: 10.1182/blood-2013-12-543363. Epub 2014 Feb 28. Blood. 2014. PMID: 24585775 Free PMC article.
Similar articles
-
The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation.J Clin Invest. 2007 Aug;117(8):2250-9. doi: 10.1172/JCI31024. J Clin Invest. 2007. PMID: 17627302 Free PMC article.
-
A talin mutant that impairs talin-integrin binding in platelets decelerates αIIbβ3 activation without pathological bleeding.Blood. 2014 Apr 24;123(17):2722-31. doi: 10.1182/blood-2013-12-543363. Epub 2014 Feb 28. Blood. 2014. PMID: 24585775 Free PMC article.
-
Kindlin supports platelet integrin αIIbβ3 activation by interacting with paxillin.J Cell Sci. 2017 Nov 1;130(21):3764-3775. doi: 10.1242/jcs.205641. Epub 2017 Sep 27. J Cell Sci. 2017. PMID: 28954813 Free PMC article.
-
Talin-dependent integrin signalling in vivo.Thromb Haemost. 2009 Jun;101(6):1020-4. Thromb Haemost. 2009. PMID: 19492142 Review.
-
Procoagulant platelets and the pathways leading to cell death.Semin Thromb Hemost. 2015 Jun;41(4):405-12. doi: 10.1055/s-0034-1544002. Epub 2015 Apr 16. Semin Thromb Hemost. 2015. PMID: 26035696 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical